Last updated on May 2019

Ovarian Platelet Rich Plasma Treatment for Poor Responders


Brief description of study

Autologous ovarian Platelet Rich Plasma (PRP) treatment may enable ovarian rejuvenation, increase of AMH levels, and improved oocyte retrieval yield in poor responders undergoing single IVF cycle.

Detailed Study Description

The specific prospective clinical investigation, aims to answer whether autologous Platelet reactivation of the ovarian tissue functionality.

PRP is blood plasma prepared from fresh whole blood that has been enriched with platelets. It is collected from peripheral veins and contains several growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor (TGF) and other cytokines all of which stimulate tissue proliferation and growth. PRP has been employed in several medical conditions in Orthopedics, Dermatology, Ophthalmology for wound healing. It's efficacy in ovarian rejuvenation and reactivation and endometrial regeneration has not been fully elucidated.

The aim of this study is to evaluate the effectiveness of ovarian PRP injection, in order to reactivate ovarian function.

Clinical Study Identifier: NCT03937661

Find a site near you

Start Over

Genesis AC

Athens, Greece
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.